Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group.

Lancet. 2008 Mar 29;371(9618):1085-97. doi: 10.1016/S0140-6736(08)60486-9.

PMID:
18374841
2.

Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, Fleischhacker WW; EUFEST Study Group.

J Clin Psychiatry. 2011 Jul;72(7):955-61. doi: 10.4088/JCP.10m06529.

PMID:
21824456
3.

One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.

San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.

Psychiatry Res. 2012 Dec 30;200(2-3):693-701. doi: 10.1016/j.psychres.2012.07.005. Epub 2012 Sep 3.

PMID:
22954905
4.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

5.

Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).

Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS; EUFEST study group.

Schizophr Res. 2009 Dec;115(2-3):97-103. doi: 10.1016/j.schres.2009.09.019. Epub 2009 Oct 9.

PMID:
19819114
6.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):611-22.

PMID:
16585435
7.

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.

Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.

Schizophr Res. 2008 Jan;98(1-3):8-15. Epub 2007 Jun 26.

PMID:
17596914
8.

Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Volavka J, Czobor P, Citrome L, Van Dorn RA.

CNS Spectr. 2014 Oct;19(5):374-81. doi: 10.1017/S1092852913000849. Epub 2013 Nov 28. Erratum in: CNS Spectr. 2014 Oct;19(5):466.

9.

Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.

Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S.

Schizophr Bull. 2012 Jun;38(4):845-53. doi: 10.1093/schbul/sbq172. Epub 2011 Feb 9.

10.

New generation antipsychotics for first episode schizophrenia.

Rummel C, Hamann J, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2003;(4):CD004410. Review.

PMID:
14584012
11.

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Correll CU, Leucht S, Kane JM.

Am J Psychiatry. 2004 Mar;161(3):414-25. Review.

PMID:
14992963
12.

[Current pharmacotherapy of schizophrenia].

Bitter I.

Orv Hetil. 2004 Jan 18;145(3):105-9. Review. Hungarian.

PMID:
15027331
13.

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.

Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA.

World J Biol Psychiatry. 2009;10(4 Pt 3):710-8. doi: 10.1080/15622970802269589.

PMID:
18803070
14.

Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.

Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.

J Med Assoc Thai. 2005 Sep;88(9):1267-77.

PMID:
16536115
15.

Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia.

McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, Hasan SM.

Br J Psychiatry. 2006 Nov;189:433-40.

PMID:
17077434
16.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
17.

Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.

Zedkova I, Dudova I, Urbanek T, Hrdlicka M.

Neuro Endocrinol Lett. 2011;32(5):667-70.

PMID:
22167144
18.

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

Dossenbach M, Arango-Dávila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assunção S.

J Clin Psychiatry. 2005 Aug;66(8):1021-30.

PMID:
16086618
19.

Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.

Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS; Eufest Study Group.

Eur Neuropsychopharmacol. 2013 Mar;23(3):196-204. doi: 10.1016/j.euroneuro.2012.04.019. Epub 2012 May 28.

PMID:
22647933
20.

Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Ortiz-Garcia de la Foz V, Martínez-Garcia O, Valdizan EM, Vazquez-Barquero JL.

J Clin Psychopharmacol. 2013 Apr;33(2):215-20. doi: 10.1097/JCP.0b013e3182825c1e.

PMID:
23422371

Supplemental Content

Support Center